Clinical Research Directory

Inclusion Criteria: 1. Pathologically confirmed invasive breast cancer ; 2. Breast MRI showing stages IIB to IIIC (2017 AJCC 8th edition staging); 3. Clinical staging confirmed by chest MRI and/or axillary ultrasound, as well as CT scans of the neck, abdomen, and pelvis, and bone scintigraphy, including T and N staging and assessment of distant metastasis; 4. Karnofsky performance score ≥80 or ECOG performance status of 0-1; 5. No history of allergies to doxorubicin, cyclophosphamide, paclitaxel/docetaxel; 6. No prior exposure to radiotherapy, chemotherapy, endocrine therapy, targeted therapy, or immunotherapy. Exclusion Criteria: 1. History of malignancy at other sites, excluding curable non-melanoma skin cancer and carcinoma in situ of the cervix; 2. Inability to complete MRI; 3. Inflammatory breast cancer; 4. Bilateral or multifocal primary tumors; 5. Active infection currently present; clinically evident heart disease; myocardial infarction or cerebrovascular accident within 6 months prior to enrollment.